A Look at Bruker (BRKR) Valuation After Weaker Q3 Earnings and Lower 2025 Guidance

Simply Wall St.11-05

Bruker (BRKR) just delivered its third quarter results, revealing a move from net income last year to a net loss in this period, along with a sizable goodwill impairment. The company also revised its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581250917?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2025-11-05 15:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581250917","market":"hk","top_or_hot":-1,"title":"A Look at Bruker (BRKR) Valuation After Weaker Q3 Earnings and Lower 2025 Guidance","media":"Simply Wall St.","content":"<div>\n<p>Bruker (BRKR) just delivered its third quarter results, revealing a move from net income last year to a net loss in this period, along with a sizable goodwill impairment. The company also revised its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/a-look-at-bruker-brkr-valuation-after-weaker-q3-earnings-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look at Bruker (BRKR) Valuation After Weaker Q3 Earnings and Lower 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look at Bruker (BRKR) Valuation After Weaker Q3 Earnings and Lower 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-05 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/a-look-at-bruker-brkr-valuation-after-weaker-q3-earnings-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bruker (BRKR) just delivered its third quarter results, revealing a move from net income last year to a net loss in this period, along with a sizable goodwill impairment. The company also revised its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/a-look-at-bruker-brkr-valuation-after-weaker-q3-earnings-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRKR","symbol_name":"布鲁克","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/a-look-at-bruker-brkr-valuation-after-weaker-q3-earnings-and","article_id":"2581250917","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/a-look-at-bruker-brkr-valuation-after-weaker-q3-earnings-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581250917","pubTimestamp":1762328707,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bruker (BRKR) just delivered its third quarter results, revealing a move from net income last year to a net loss in this period, along with a sizable goodwill impairment. The company also revised its full-year outlook lower, citing softer demand and earnings dilution.\nSee our latest analysis for Bruker.\nDespite the string of recent updates, including lowered guidance and fresh dividend announcements, Bruker’s share price has shown surprising resilience, bouncing more than 29% over the past 90...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BRKR":"布鲁克"},"translate_title":"第三季度盈利疲软和2025年指引下调后布鲁克(BRKR)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRKR":1.5},"content_text":"Bruker (BRKR) just delivered its third quarter results, revealing a move from net income last year to a net loss in this period, along with a sizable goodwill impairment. The company also revised its full-year outlook lower, citing softer demand and earnings dilution. See our latest analysis for Bruker. Despite the string of recent updates, including lowered guidance and fresh dividend announcements, Bruker’s share price has shown surprising resilience, bouncing more than 29% over the past 90 days. However, momentum still has a way to go, with the 1-year total shareholder return at -31%, reflecting a business working through some tough headwinds while investor sentiment cautiously recovers. If today’s turnaround in Bruker caught your attention, now could be the perfect moment to broaden your search and discover fast growing stocks with high insider ownership With shares still trading more than 18% below analyst targets, the question remains: is Bruker’s current weakness an invitation for long-term investors, or does the market already reflect muted future growth in the price? AdvertisementMost Popular Narrative: 15.6% Undervalued Bruker's narrative fair value of $47.82 stands well above its recent close at $40.38, hinting at potential upside should consensus expectations play out. This popular viewpoint sets the stage for a closer look at the drivers behind these projections.  Bruker's expanded cost reduction program (targeting $100 to $120 million of annualized savings, mainly realized in FY26) is set to drive at least 300 basis points of operating margin expansion and double-digit EPS growth even in a flat to muted revenue environment, improving net margins and earnings quality.  Read the complete narrative. Want to see what underpins that bullish view? Analysts are betting on a margin leap and profit surge, grounded in bold turnaround assumptions. The full narrative reveals the growth levers and specific numbers powering this valuation and could flip your take on Bruker's outlook. Result: Fair Value of $47.82 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent academic funding cuts and ongoing market uncertainty remain key risks. These factors could disrupt Bruker's recovery trajectory and future earnings. Find out about the key risks to this Bruker narrative. Another View: What Does the SWS DCF Model Say? While analyst price targets suggest upside for Bruker, our DCF model lands on a different note. It currently values the shares below the market price, which indicates the stock may be overvalued if you rely on long-term cash flow forecasts. Which scenario offers the truer picture for investors? Look into how the SWS DCF model arrives at its fair value. BRKR Discounted Cash Flow as at Nov 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Bruker for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 840 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Bruker Narrative If you have a different perspective or want to dig deeper into the numbers yourself, you can craft your own view in just a few minutes. Do it your way A great starting point for your Bruker research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Looking for More Smart Opportunities? Don’t let your next big winner pass you by. Simply Wall Street’s powerful screeners reveal trends before the crowd and help you make confident investment decisions.  Target untapped value and strengthen your portfolio by zeroing in on these 840 undervalued stocks based on cash flows offering upside based on strong cash flows. Capitalize on innovation when you spot potential breakouts among these 26 AI penny stocks leading advancements in artificial intelligence. Boost your passive income by tapping into these 20 dividend stocks with yields > 3% with attractive yields over 3% and strong financial health.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bruker might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581250917","isCrawlerRequest":true}